• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ferring Pharmaceuticals - Product Pipeline Review - Q4 2010 - Product Image

Ferring Pharmaceuticals - Product Pipeline Review - Q4 2010

  • ID: 1448562
  • December 2010
  • 40 pages
  • Global Markets Direct

Ferring Pharmaceuticals – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Ferring Pharmaceuticals - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ferring Pharmaceuticals - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ferring Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Ferring Pharmaceuticals Snapshot
Ferring Pharmaceuticals Overview
Key Information
Key Facts
Ferring Pharmaceuticals – Research and Development Overview
Key Therapeutic Areas
Ferring Pharmaceuticals – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Ferring Pharmaceuticals – Pipeline Products Glance
Ferring Pharmaceuticals – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ferring Pharmaceuticals Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ferring Pharmaceuticals–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ferring Pharmaceuticals – Drug Profiles
FIRMAGON-
Product Description
Mechanism of Action
R&D Progress
MINIRIN Melt
Product Description
Mechanism of Action
R&D Progress
FE 202158
Product Description
Mechanism of Action
R&D Progress
GnRH Patch
Product Description
Mechanism of Action
R&D Progress
Recombinant Hormones For Ovulation Induction
Product Description
Mechanism of Action
R&D Progress
Ferring Pharmaceuticals – Pipeline Analysis
Ferring Pharmaceuticals – Pipeline Products by Therapeutic Class
Ferring Pharmaceuticals Pipeline Products By Target
Ferring Pharmaceuticals – Pipeline Products by Route of Administration
Ferring Pharmaceuticals – Pipeline Products by Molecule Type
Ferring Pharmaceuticals – Recent Pipeline Updates
Ferring Pharmaceuticals – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 06, 2010: Ferring Announces Publication Of Data From Pivotal Phase III LYSTEDA Study In Journal Of Obstetrics And Gynecology
Aug 03, 2010: Ferring Launches LYSTEDA For Women With Cyclic Heavy Menstrual Bleeding
Jun 21, 2010: Ferring Announces Commercial Availability Of LYSTEDA In US For Treatment Of Women With Cyclic Heavy Menstrual Bleeding
Jun 02, 2010: FIRMAGON Results In Fast, Long-Term Suppression Of Testosterone In Prostate Cancer Patients Without Initial Testosterone Surge
Jun 01, 2010: Phase III Extension Study With FIRMAGON Shows Continued Benefits For Prostate Cancer Patients Beyond One Year
May 19, 2010: Ferring Presents Findings From Clinical Trials Evaluating LYSTEDA For Treatment Of Women With Cyclic Heavy Menstrual Bleeding
Dec 21, 2009: FIRMAGON has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients
Dec 04, 2009: Ferring Pharmaceuticals Announces Phase III Pivotal Study Results Of FIRMAGON For The Treatment Of Prostate Cancer
Aug 04, 2009: Ferring Pharmaceuticals Announces Trade Name FIRMAGON For Advanced Prostate Cancer Treatment
Apr 27, 2009: Ferring Pharmaceuticals launches Phase IIIB Trial Of Degarelix As Intermittent Therapy
Financial Deals Landscape
Ferring Pharmaceuticals, Deals Volume Summary, 2004 to YTD 2010
Ferring Pharmaceuticals, Deals Summary By Region, 2004 to YTD 2010
Ferring Pharmaceuticals, Deals Summary, 2004 to YTD 2010
Ferring Pharmaceuticals Detailed Deal Summary
BioGaia Enters Into Distribution Agreement With Ferring Pharmaceuticals
BioGaia Enters Into Co-Marketing Agreement With Ferring Pharmaceuticals
BioGaia Enters Into Co-Marketing Agreement With Ferring Pharmaceuticals
Licensing Agreements
Ferring Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS